BR112023002180A2 - Terapia de combinação com antagonistas de receptor de adenosina - Google Patents

Terapia de combinação com antagonistas de receptor de adenosina

Info

Publication number
BR112023002180A2
BR112023002180A2 BR112023002180A BR112023002180A BR112023002180A2 BR 112023002180 A2 BR112023002180 A2 BR 112023002180A2 BR 112023002180 A BR112023002180 A BR 112023002180A BR 112023002180 A BR112023002180 A BR 112023002180A BR 112023002180 A2 BR112023002180 A2 BR 112023002180A2
Authority
BR
Brazil
Prior art keywords
adenosine receptor
combination therapy
receptor antagonists
combination
mammals
Prior art date
Application number
BR112023002180A
Other languages
English (en)
Inventor
Fan Peidong
Yao Lina
Liu Jiwen
Elzein Elfatih
Original Assignee
Teon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teon Therapeutics Inc filed Critical Teon Therapeutics Inc
Publication of BR112023002180A2 publication Critical patent/BR112023002180A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

TERAPIA DE COMBINAÇÃO COM ANTAGONISTAS DE RECEPTOR DE ADENOSINA. Trata-se de compostos, composições, formulações e métodos para modular o receptor de adenosina A2B em combinação com inibidores de ponto de verificação imune em mamíferos com câncer.
BR112023002180A 2020-08-07 2021-08-06 Terapia de combinação com antagonistas de receptor de adenosina BR112023002180A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062857P 2020-08-07 2020-08-07
PCT/US2021/044935 WO2022032091A1 (en) 2020-08-07 2021-08-06 Combination therapy with adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
BR112023002180A2 true BR112023002180A2 (pt) 2023-05-02

Family

ID=80117696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002180A BR112023002180A2 (pt) 2020-08-07 2021-08-06 Terapia de combinação com antagonistas de receptor de adenosina

Country Status (9)

Country Link
US (1) US20240041889A1 (pt)
EP (1) EP4192916A1 (pt)
JP (1) JP2023536996A (pt)
CN (1) CN116194537A (pt)
AU (1) AU2021320389A1 (pt)
BR (1) BR112023002180A2 (pt)
CA (1) CA3190685A1 (pt)
MX (1) MX2023001571A (pt)
WO (1) WO2022032091A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法
WO2024015372A1 (en) * 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US20200093789A1 (en) * 2017-05-10 2020-03-26 The General Hospital Corporation Cancer Treatment with a CXCL12 Signaling Inhibitor and an Immune Checkpoint Inhibitor
BR112020018158A2 (pt) * 2018-03-05 2021-02-02 Teon Therapeutics, Inc. antagonistas de receptor de adenosina e usos dos mesmos
JP2022500496A (ja) * 2018-09-11 2022-01-04 アイテオ ベルギウム エスエー Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ

Also Published As

Publication number Publication date
CA3190685A1 (en) 2022-02-10
US20240041889A1 (en) 2024-02-08
WO2022032091A1 (en) 2022-02-10
CN116194537A (zh) 2023-05-30
JP2023536996A (ja) 2023-08-30
AU2021320389A1 (en) 2023-03-02
MX2023001571A (es) 2023-04-13
EP4192916A1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
BR112023002180A2 (pt) Terapia de combinação com antagonistas de receptor de adenosina
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1126066T1 (el) Υποκατεστημενα παραγωγα θειενο[2,3-d]πυριμιδινης ως αναστολεις της μενινης-mll και μεθοδοι χρησης
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
BR112022000641A2 (pt) Modificação genética de célula efetora imune e uso da mesma
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
CY1121831T1 (el) Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk
PH12021550152A1 (en) Anti-cd112r compositions and methods
BR112018068461A2 (pt) conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
BR112016009200A8 (pt) uso de um inibidor de btk e um inibidor imune do ponto de verificação
BR112018008877A2 (pt) inibidores de ret
CR20160449A (es) Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos
BR112017020054A2 (pt) anticorpos para icos
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2017013178A (es) Terapia de combinacion para cancer.
NZ739250A (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
CY1120076T1 (el) Μια κατασκευη μεταφορας, ενα συστημα μεταφορας και μια μεθοδος για την μεταφορα lng και/ή ηλεκτρικης ισχυος
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
NZ725459A (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
DOP2020000020A (es) Anticuerpos anti-cd137
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada